93 related articles for article (PubMed ID: 31167767)
1. Cascade of immunologic adverse events related to pembrolizumab treatment.
Dhenin A; Samartzi V; Lejeune S; Seront E
BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31167767
[TBL] [Abstract][Full Text] [Related]
2. Managing suspected myasthenia gravis and myositis induced by pembrolizumab in a Jehovah's Witness sarcoma patient.
Hutchinson A; Eskens D; Chan A; Bhargava A; Bycroft R
J Oncol Pharm Pract; 2024 Jul; 30(5):950-953. PubMed ID: 38523425
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report.
Kiaei B; Chaudhry M; Banerjee S; Brewer J; Chen Y; Khasiyev F; Guzman MA; Hayat G
BMC Neurol; 2024 Jun; 24(1):184. PubMed ID: 38824498
[TBL] [Abstract][Full Text] [Related]
4. Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment.
Soman B; Dias MC; Rizvi SAJ; Kardos A
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593626
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab-induced agranulocytosis.
Fernández Martínez V; García-Avello Fernández-Cueto A; Valencia Soto CM; Barbadillo Villanueva S; Ochagavía Sufrategui M; Rioja Carrera M; Alonso Buznego LA; Valero Domínguez M
J Oncol Pharm Pract; 2024 Jun; 30(4):767-771. PubMed ID: 38291678
[TBL] [Abstract][Full Text] [Related]
6. Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report.
Botta C; Agostino RM; Dattola V; Cianci V; Calandruccio ND; Bianco G; Mafodda A; Maisano R; Iuliano E; Orizzonte G; Mazzacuva D; Falzea AC; Saladino RE; Giannicola R; Restifo G; Aguglia U; Caraglia M; Correale P
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200673
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection.
Sisman G; Barbur E; Saka D; Erdamar Cetin S
Cancer Immunol Immunother; 2021 Aug; 70(8):2385-2388. PubMed ID: 33481043
[TBL] [Abstract][Full Text] [Related]
8. Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis.
Zhao S; Zhou Y; Sun W; Li Z; Wang C
Clin Exp Immunol; 2023 Mar; 211(2):85-92. PubMed ID: 36426591
[TBL] [Abstract][Full Text] [Related]
9. Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.
Baarslag MA; Heimovaara JH; Borgers JSW; van Aerde KJ; Koenen HJPM; Smeets RL; Buitelaar PLM; Pluim D; Vos S; Henriet SSV; de Groot JWB; van Grotel M; Rosing H; Beijnen JH; Huitema ADR; Haanen JBAG; Amant F; Gierenz N
N Engl J Med; 2023 Nov; 389(19):1790-1796. PubMed ID: 37937778
[TBL] [Abstract][Full Text] [Related]
10. Chronic polyradiculoneuropathy associated with pembrolizumab for bladder cancer.
Kobayashi Y; Iijima K; Kondo Y; Yamamoto K; Sekijima Y
Acta Neurol Belg; 2024 Jun; 124(3):1063-1065. PubMed ID: 38010574
[No Abstract] [Full Text] [Related]
11. Online Patient Attitudes Toward Cutaneous Immune-Related Adverse Events Attributed to Nivolumab and Pembrolizumab: Sentiment Analysis.
Powers CM; Yang AK; Verma H; Orloff J; Piontkowski AJ; Gulati N
JMIR Dermatol; 2024 May; 7():e53792. PubMed ID: 38696235
[No Abstract] [Full Text] [Related]
12. Immune checkpoint inhibitor associated diarrhoea.
Al-Hussainy A; Adams J; Simmons J; Kennedy J
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38719255
[TBL] [Abstract][Full Text] [Related]
13. Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy?
Hamimed M; Devillier R; Weiller PJ; Marin C; Schiano JM; Belmecheri N; Etienne-Grimaldi MC; Ciccolini J; Harbi S
Cancer Chemother Pharmacol; 2024 Jun; 93(6):627-632. PubMed ID: 37957436
[TBL] [Abstract][Full Text] [Related]
14. Rapid onset pembrolizumab-induced inflammatory arthritis diagnosed using musculoskeletal ultrasound.
Harnden K; Di Matteo A; Howell K; Mankia K
BMJ Case Rep; 2024 Apr; 17(4):. PubMed ID: 38663895
[TBL] [Abstract][Full Text] [Related]
15. Refractory pembrolizumab immunotherapy-related colitis requiring biological therapy in an inactive HBcAb carrier.
Rasheed N; Anand R; Maddox M; Reyes C
BMJ Case Rep; 2023 Sep; 16(9):. PubMed ID: 37751983
[TBL] [Abstract][Full Text] [Related]
16. Ravulizumab in myasthenic crisis: the first case report.
Konen FF; Jendretzky KF; Ratuszny D; Schuppner R; Sühs KW; Pawlitzki M; Ruck T; Meuth SG; Skripuletz T
J Neurol; 2024 May; 271(5):2898-2901. PubMed ID: 38388927
[No Abstract] [Full Text] [Related]
17. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
Abou Alaiwi S; Xie W; Nassar AH; Dudani S; Martini D; Bakouny Z; Steinharter JA; Nuzzo PV; Flippot R; Martinez-Chanza N; Wei X; McGregor BA; Kaymakcalan MD; Heng DYC; Bilen MA; Choueiri TK; Harshman LC
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066646
[TBL] [Abstract][Full Text] [Related]
18. [A case of myasthenia gravis and myositis induced by pembrolizumab].
Noda T; Kageyama H; Miura M; Tamura T; Ito H
Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
[TBL] [Abstract][Full Text] [Related]
19. Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.
Sugisaka J; Toi Y; Taguri M; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
JMA J; 2020 Jan; 3(1):58-66. PubMed ID: 33324776
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
